Gyre Therapeutics, Inc. GYRE Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s change in accrued liabilities?
- Gyre Therapeutics, Inc. (GYRE) reported change in accrued liabilities of $683K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Gyre Therapeutics, Inc.'s change in accrued liabilities decreased by 84.6% year-over-year, from $4.44M to $683K.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.